Prue C. Weideman

Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Kelly‐Anne Phillips, Roger L. Milne, Matti A. Rookus et al. · Journal of Clinical Oncology · 2013 · 168 citations · Full text

10-year performance of four models of breast cancer risk: a validation study

Mary Beth Terry, Yuyan Liao, Alice S. Whittemore et al. · The Lancet Oncology · 2019 · 165 citations

Epidemiology, Preventive Medicine, Cancer Epidemiology +15

Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort

Kelly‐Anne Phillips, Phyllis Butow, Ailsa E. Stewart et al. · Familial Cancer · 2005 · 62 citations

Nursing, Family Medicine, Breast Oncology +9

Do<i>BRCA1</i>and<i>BRCA2</i>Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer

Ian Collins, Roger L. Milne, Sue Anne McLachlan et al. · Journal of Clinical Oncology · 2013 · 50 citations · Full text

Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre

Robert J. MacInnis, Adrian Bickerstaffe, Carmel Apicella et al. · British Journal of Cancer · 2013 · 48 citations · Full text